Scholarlink

Background <p>This study investigates how variations in Major Depressive Disorder (MDD) symptoms (HAM-D) are associated in a predictive model with randomized clinical trial (RCT) arm assignment between SSRIs and SNRIs.</p> Methods <p>We applied explainable counterfactual reasoning with counterfactual explanations (CFs) to assess the impact of specific symptom changes on model-predicted RCT arm assignment.</p> Results <p>Across 17 classifiers, CatBoost achieved the highest performance; typical test metrics ranged &#xa0;0.74–0.78 with best ROC-AUC &#xa0;0.7640. Sample-based CFs revealed both local and global feature importance of individual symptoms in medication selection.</p> Conclusion <p>Counterfactual reasoning highlights which MDD symptoms the model uses to distinguish SSRI vs. SNRI trial assignments, supporting interpretable AI-based decision support while requiring prospective real-world validation beyond the RCT context. Future work should validate these findings on more diverse cohorts and refine algorithms for clinical deployment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Explainable counterfactual reasoning in depression medication selection at multi-levels (personalized and population)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月4日

查看全文
  • Xinyu Qin,
  • Mark H. Chignell,
  • Alexandria Greifenberger,
  • Sachinthya Lokuge,
  • Elssa Toumeh,
  • Tia Sternat,
  • Martin Katzman,
  • Lu Wang

摘要

Background

This study investigates how variations in Major Depressive Disorder (MDD) symptoms (HAM-D) are associated in a predictive model with randomized clinical trial (RCT) arm assignment between SSRIs and SNRIs.

Methods

We applied explainable counterfactual reasoning with counterfactual explanations (CFs) to assess the impact of specific symptom changes on model-predicted RCT arm assignment.

Results

Across 17 classifiers, CatBoost achieved the highest performance; typical test metrics ranged  0.74–0.78 with best ROC-AUC  0.7640. Sample-based CFs revealed both local and global feature importance of individual symptoms in medication selection.

Conclusion

Counterfactual reasoning highlights which MDD symptoms the model uses to distinguish SSRI vs. SNRI trial assignments, supporting interpretable AI-based decision support while requiring prospective real-world validation beyond the RCT context. Future work should validate these findings on more diverse cohorts and refine algorithms for clinical deployment.